GW Pharmaceuticals plc GWPH, is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. This is one of the most exciting growth stories in medicine right now. Within the past quarter, the Zacks Consensus Estimate for GWPH's full-year earnings has moved higher by double digits. This is a sign of improving analyst sentiment and a positive earnings outlook trend. GW Pharmaceuticals is performing better than its sector in terms of year-to-date returns. Average analyst price targets are now over $200 based on the blockbuster sales growth potential ($1-2 billion) of the only FDA-approved cannabis-derived drug maker, who also happens to have a 20-year track record of innovation and a burgeoning pipeline.Chegg, Inc. CHGG, rents and sells print textbooks; and provides eTextbooks, and other supplemental educational materials and services. The company is coming off a stronger-than-projected second quarter and its business model, which has expanded, appears strong. Looking ahead, our current Zacks Consensus Estimates call for the company’s third-quarter 2019 revenue to surge by double digits. Fourth quarter sales are projected to jump by double digits as well. Overall 2019 revenue is expected to climb roughly 25%. Peeking further down the road, Chegg’s fiscal 2020 revenue is projected to pop approximately 19.4% above our current year estimate.The Hottest Tech Mega-Trend of All Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.See Zacks' 3 Best Stocks to Play This Trend >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Chegg, Inc. (CHGG): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research